MannKind raises $50M to fund Furoscix milestone payment
What's the deal? MannKind Corporation (Nasdaq: MNKD) has raised roughly $50 million in a private placement led by Frazier Life SciencesDealroom has a profile for this one. Try Dealroom →, a longstanding biotech investment firm. The biopharmaceutical company sold institutional investors 10,440,838 shares of common stock plus pre-funded warrants for up to 2,412,632 more, at $3.89 per share.
What's the endgame? MannKind develops treatments for cardiometabolic and orphan lung diseases. It plans to use the proceeds for general corporate purposes, including a $45 million contingent value rights payment triggered by the US Food and Drug Administration's approval of Furoscix ReadyFlow.
Why now? The financing closes on or about July 24, 2026, timed to cover the milestone payment the regulatory approval set in motion. The pre-funded warrants carry an exercise price of $0.01 per share and do not expire until exercised in full.
What's next? The securities were not registered under the Securities Act and were sold under a private-placement exemption. MannKind has agreed to file a registration statement with the Securities and Exchange Commission to cover the resale of the shares.
The signal: The raise reads as a quick re-raise: a listed drugmaker tapping institutional capital to clear a near-term obligation rather than fund long-range research. It signals confidence from a specialist investor that MannKind's newly approved product can carry its costs.
Read more: wallstreet-online.de
Image credit: foteih
